SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network (AVT) is capturing attention following the formal incorporation of its DAO in the UAE and strategic partnerships to bolster its Aventus Cloud offerings. The community is buzzing about AVT's enterprise-grade technology, Polkadot integration, and low market capitalization, anticipating a significant breakout.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a surge in attention following reports of a strategic partnership with Novo Nordisk to distribute weight-loss drugs, resolving their prior dispute. The market is now actively discussing the potential for a significant short squeeze, fueled by high short interest and the dramatic nature of this unexpected collaboration.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is currently a major focus amid escalating geopolitical tensions with Iran, which have significantly disrupted oil tanker traffic through the critical Strait of Hormuz. The market is keenly watching for whether this signals a prolonged supply squeeze or a temporary "fear premium" that could be quickly reversed by a resolution or market intervention.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI ($FAI) is rapidly gaining attention following a significant price surge, with "great AI news" and the overall enthusiasm for AI crypto driving the conversation. Community members are actively debating its potential for exponential growth against concerns of high volatility, with its presence on the Base network adding to the speculative interest.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is generating buzz due to increasing community confidence in Miplyffa's impending European approval and robust U.S. sales momentum, alongside the strategic appointment of a new CFO seen as a catalyst for enhanced commercialization and potential M&A activity.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amid intense community discussion surrounding the anticipated "Clarity Act," with many believing its passage will establish the token as a vital digital commodity for collateralized payments and drive significant institutional adoption. This bullish outlook, however, is heavily counterbalanced by widespread frustration and skepticism over AMP's persistent downtrend and historical price volatility among long-term holders.

Literally a dog wif a hat, dogwifhat (WIF) is a meme coin that's part of the ever-growing ecosystem of digital currencies on the Solana blockchain. This token brings a lighthearted twist to cryptocurrency, featuring a playful dog with a hat as its mascot, symbolising a more whimsical approach to the often serious domain of digital finance.

dogwifhat

Dogwifhat ($WIF) is trending amidst extreme price volatility and widespread investor frustration, as the community laments persistent dumping and a struggle to maintain gains, despite some expressing optimism for an impending rebound and altcoin rally.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending as investors digest its recent positive earnings, significant debt reduction, and the game-changing acquisition of Valaris, positioning it as a deepwater drilling powerhouse. The community is actively discussing perceived undervaluation and frustration over the stock's current price action, which many feel is disconnected from surging oil prices driven by escalating geopolitical tensions.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending as an activist investor's significant stake and a new CEO fuel community debate over a potential turnaround, directly clashing with recent weak guidance, rising oil prices, and broader geopolitical risks impacting the cruise sector.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is a focal point of discussion amid persistent fraud allegations and concerns over its subprime lending practices, with many investors debating the stock's valuation and its seemingly artificial price movements attributed to ongoing market manipulation and options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Klotho Neurosciences Expands Into Mining With Greenland Mines Deal

Klotho Neurosciences acquires Greenland Mines, gaining access to Skaergaard Project with an estimated $68 billion palladium and gold resource.read more...

KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR

KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE...

Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)

Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the 'Klotho Clock,' a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial...

Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence

Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ('s-KL') Isoform of the Human Klotho Gene Sequence Klotho Neurosciences Receives...

Klotho Neurosciences to Present at the Biotech Showcase 2026

Klotho Neurosciences to Present at the Biotech Showcase 2026 Klotho Neurosciences to Present at the Biotech Showcase 2026 PR Newswire NEW YORK, Jan. 8, 2026 NEW YORK, Jan. 8, 2026 /PRNewswire...

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award...

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston PR Newswire NEW YORK, Oct. 16, 2025 NEW YORK, Oct. 16, 2025...

Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202.The designation is reserved for treatments targeting rare diseases and comes with several incentives to support development.&nbsp;These include seven years of market exclusivity, tax credits for clinical trials, and a waiver of the generic drug user fee amendments (GDUFA) user fee, independent of existing intellectual property rights.At the close on Thursday, shares of&nbsp;<a href="https://stocktwits.com/symbol/KLTO">Klotho Neurosciences</a> rose 6.6% to $1.46, before slipping 6.9% to $1.36 in after-hours trading.Last month, the company reported efforts to move forward with manufacturing and process development in preparation for clinical trials of KLTO-202.&nbsp;Klotho holds rights to a unique RNA splice variant of the human alpha‑Klotho gene, licensed from the Autonomous University of Barcelona.&nbsp;This variant produces the secreted form of Klotho protein (s‑KL), known for its neuroprotective properties in the brain and spinal cord.Animal studies conducted in mouse and non-human primate models of accelerated aging, Alzheimer's disease, and ALS have demonstrated that boosting s‑KL through gene therapy yields therapeutic benefits across all tested models, according to peer-reviewed journals.&nbsp;These findings support KLTO-202’s progression into clinical development.The company expects that process development and manufacturing will take about eight months, followed by four to six months of FDA meetings, mandated animal safety studies, an investigational new drug (IND) filing, and site preparations.&nbsp;A single-dose Phase I/II trial in ALS patients is planned for the third quarter of next year.&nbsp;In a statement, CEO Joseph Sinkule said that the therapy’s goal is to deliver therapeutic s‑KL concentrations to blood, brain, and muscle tissue.KLTO-202, which uses a muscle-specific desmin promoter to drive s‑KL expression at the neuromuscular junction, remains unapproved for human use.On Stocktwits, retail sentiment for Kloto was ‘bullish’ amid ‘high’ message volume.Kloto’s stock has more than doubled in value so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/china-s-byd-chery-accused-of-subsidy-misuse-as-ev-audit-flags-121-m-in-claims/ch8c5XCR5mQ">China’s BYD, Chery Accused Of Subsidy Misuse As EV Audit Flags $121M In Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kloto Neurosciences (KLTO) said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. (Photo credit: Getty Images)

Klotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene Therapy

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical trials, and a waiver of the user fee for its ALS gene therapy.

Equity

Klotho Neurosciences (KLTO) shares exploded over 780% on Monday, their biggest single-day gain on record, after the company announced breakthrough preclinical results tied to its anti-aging gene therapy.The Omaha, Nebraska-based biotech said boosting levels of a naturally occurring protein called s-KL (secreted Klotho) extended lifespan in mice by 20% and reduced signs of aging across multiple organ systems.&nbsp;The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models."The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span," said CEO Joseph Sinkule.&nbsp;Klotho owns exclusive global rights to the patented therapy, based on pioneering work from researchers at Universitat Autònoma de Barcelona. The company said its patent coverage spans the U.S., Europe, and China.Earlier studies had shown that mice with increased Klotho expression could live up to 40% longer.Retail Traders Go WildThe update triggered a retail frenzy on Stocktwits as 24-hour message volume about KLTO jumped by 250,400% — the biggest surge in the healthcare sector — while the follower count spiked by over 134%.Sentiment score peaked at ‘extremely bullish’ levels (100/100) by the end of Monday.<figure class="image"><img style="aspect-ratio:1318/914;" src="https://news.stocktwits-cdn.com/KLTO_sentiment_and_message_volume_as_of_Jun_9_png_d3adf0d02d.webp" alt="KLTO sentiment and message volume as of Jun 9.png" width="1318" height="914"><figcaption>KLTO sentiment and message volume as of Jun 9. | source: Stocktwits</figcaption></figure>One user predicted the stock would surge nearly fivefold to $5.<stembedurl>https://stocktwits.com/Kcricket33/message/617354438</stembedurl>"Pretty wild news, obviously digested well today… will watch for continuation tomorrow using the pivot of today's highs in confluence with trend support as entry criteria. Range to $2.8, $3+," said another.<stembedurl>https://stocktwits.com/KevMomentum/message/617353716</stembedurl>Klotho is targeting neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, leveraging s-KL in both DNA/RNA therapies and genomics-based diagnostics.<a href="https://stocktwits.com/symbol/KLTO">KLTO stock</a> is now up over 271% YTD, returning to levels last seen in July 2024.&nbsp;However, short interest has also climbed, rising from 1.1% in January to 7.1% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon

The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models.

Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Omaha, NE.

KLTO
Klotho Neurosciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest KLTO News

KLTOKlotho Neurosciences Inc.